C Conrad1, J Lymp2, V Thompson2, C Dunn1, Z Davies1, B Chatfield3, D Nichols4, J Clancy5, R Vender6, M E Egan7, L Quittell8, P Michelson9, V Antony10, J Spahr11, R C Rubenstein12, R B Moss1, L A Herzenberg13, C H Goss2, R Tirouvanziam14. 1. Lucile Packard Children's Hospital, Center of Excellence in Pulmonary Biology, 770 Welch Rd., #350, Stanford University, Palo Alto, CA 94304, United States. 2. CFFT Therapeutics Development Network Coordinating Center, Seattle, WA. 2001 8th Avenue, Seattle, WA 98121, United States. 3. University of Utah Pediatric Pulmonology, 100N. Mario Capecchi Dr., Salt Lake City, UT 84113, United States. 4. National Jewish Health, 1400 Jackson St., Adult CF Center, Denver, CO 80206, United States. 5. Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Pulmonary Medicine, OSB 5, Cincinnati, OH 45229, United States. 6. Pennsylvania State University/Milton S. Hershey Medical Center, PO Box 850, Hershey, PA 17033, United States. 7. Yale University School of Medicine, Yale University School of Medicine, 333 Cedar St., Rm. FMP 526, New Haven, CT 06520, United States. 8. Morgan Stanley Children's Hospital of New York, Division of Pediatric Pulmonology, Columbia University Medical Center, 3959 Broadway CHC 7-701, New York, NY 10032, United States. 9. St. Louis Children's Hospital, 660 Euclid Ave., CF Center, 10th Floor NW Tower, St. Louis, MO 63110, United States. 10. University of Alabama at Birmingham, 422 Tinsley Harrison Tower, 1900 University Blvd, Birmingham, AL 35294-0006, United States. 11. Children's Hospital of Pittsburgh of UPMC, 4221 Penn Avenue, AOB Suite 3300, Pittsburgh, PA 15224, United States. 12. The Children's Hospital of Philadelphia, 34th St and Civic Center Blvd, Abramson Research Center, Room 410A, Philadelphia, PA 19104, United States. 13. Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305-5318, United States. 14. Emory+Children's Center for CF and Airways Disease Research, 2015 Uppergate Dr., Rm. 344, Emory University School of Medicine, Atlanta, GA 30322, United States.
Abstract
PURPOSE: To evaluate the effects of oral N-acetylcysteine (NAC), which replenishes systemic glutathione, on decreasing inflammation and improving lung function in CF airways. METHODS: A multicenter, randomized, double-blind proof of concept study in which 70 CF subjects receivedNAC or placebo orally thrice daily for 24 weeks. ENDPOINTS: primary, change in sputum human neutrophil elastase (HNE) activity; secondary, FEV(1) and other clinical lung function measures; and safety, the safety and tolerability of NAC and the potential of NAC to promote pulmonary hypertension in subjects with CF. RESULTS:Lung function (FEV(1) and FEF(25-75%)) remained stable or increased slightly in the NAC group but decreased in the placebo group (p=0.02 and 0.02). Log(10) HNE activity remained equal between cohorts (difference 0.21, 95% CI -0.07 to 0.48, p=0.14). CONCLUSIONS:NAC recipients maintained their lung function while placebo recipients declined (24 week FEV1 treatment effect=150 mL, p<0.02). However no effect on HNE activity and other selected biomarkers of neutrophilic inflammation were detected. Further studies on mechanism and clinical outcomes are warranted.
RCT Entities:
PURPOSE: To evaluate the effects of oral N-acetylcysteine (NAC), which replenishes systemic glutathione, on decreasing inflammation and improving lung function in CF airways. METHODS: A multicenter, randomized, double-blind proof of concept study in which 70 CF subjects received NAC or placebo orally thrice daily for 24 weeks. ENDPOINTS: primary, change in sputum humanneutrophil elastase (HNE) activity; secondary, FEV(1) and other clinical lung function measures; and safety, the safety and tolerability of NAC and the potential of NAC to promote pulmonary hypertension in subjects with CF. RESULTS: Lung function (FEV(1) and FEF(25-75%)) remained stable or increased slightly in the NAC group but decreased in the placebo group (p=0.02 and 0.02). Log(10) HNE activity remained equal between cohorts (difference 0.21, 95% CI -0.07 to 0.48, p=0.14). CONCLUSIONS:NAC recipients maintained their lung function while placebo recipients declined (24 week FEV1 treatment effect=150 mL, p<0.02). However no effect on HNE activity and other selected biomarkers of neutrophilic inflammation were detected. Further studies on mechanism and clinical outcomes are warranted.
Authors: Joshua D Chandler; Camilla Margaroli; Hamed Horati; Matthew B Kilgore; Mieke Veltman; H Ken Liu; Alexander J Taurone; Limin Peng; Lokesh Guglani; Karan Uppal; Young-Mi Go; Harm A W M Tiddens; Bob J Scholte; Rabindra Tirouvanziam; Dean P Jones; Hettie M Janssens Journal: Eur Respir J Date: 2018-10-10 Impact factor: 16.671
Authors: Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel Journal: J Cyst Fibros Date: 2016-10-27 Impact factor: 5.482
Authors: Shaopeng Yuan; Martin Hollinger; Marrah E Lachowicz-Scroggins; Sheena C Kerr; Eleanor M Dunican; Brian M Daniel; Sudakshina Ghosh; Serpel C Erzurum; Belinda Willard; Stanley L Hazen; Xiaozhu Huang; Stephen D Carrington; Stefan Oscarson; John V Fahy Journal: Sci Transl Med Date: 2015-02-25 Impact factor: 17.956
Authors: Jesse R Willis; Ester Saus; Susana Iraola-Guzmán; Elena Cabello-Yeves; Ewa Ksiezopolska; Luca Cozzuto; Luis A Bejarano; Nuria Andreu-Somavilla; Miriam Alloza-Trabado; Andrea Blanco; Anna Puig-Sola; Elisabetta Broglio; Carlo Carolis; Julia Ponomarenko; Jochen Hecht; Toni Gabaldón Journal: J Oral Microbiol Date: 2021-05-17 Impact factor: 5.474